Abrahimi, P, Qin, L, Chang, WG, et al. 2016. Blocking MHC class II on human endothelium mitigates acute rejection. JCI Insight 1: e85293.
Ahmad, G, Amiji, M. 2018. Use of CRISPR-Cas9 gene-editing tools for developing models in drug discovery. Drug Discov Today. Doi: 10.1016/j.drudis. 2018.01.04.
Alagia, A, Eritja, R. 2016. siRNA and RNAi optimization. Wiley Interdiscipl Rev RNA 7: 316–329.
Assis, AF, Oliveira, EH, Donate, PB, et al. 2014. What is the transcriptome and how is it evaluated? In Passos, GA, ed., Transcriptomics in Health and Disease, Basel, Switzerland: Springer International Publishing, 344 pp.
Barré-Sinoussi, F, Chermann, JC, Rey, F, et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220: 868–871.
Burnett, JC, Rossi, JJ, Tiemann, K. 2011. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol J 6: 1130–1146.
Chen, C, Liu, Y, Rappaport, AR, et al. 2014. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25: 652–665.
Chen, DS, Irving, BA, Hodi, FS. 2012. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death 1. Clin Cancer Res 18: 6580–6587.
Chen, F, Wang, Y, Yuan, Y, et al. 2015. Generation of B cell-deficient pigs by highly efficient CRISPR/Cas 9-mediated gene targeting. J Genet Genom 42: 437–444.
Cheong, T-C, Compagno, M, Chiarle, R. 2016. Editing of mouse and human immunoglobulin genes by CRISPR-Cas 9 system. Nat Comm 7: 10934.
Chun, TW, Carrut, L, Finzi, D, et al. 1997. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387: 183–188.
Chun, TW, Justement, JS, Lempicki, RA, et al. 2003. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus anemic HIV-infected individuals. Proc Natl Acad Sci USA 100: 1908–1913.
Cong, L, Ran, FA, Cox, D, et al. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339: 819–823.
Cyranoski, D. 2016. First trial of CRISPR in people: Chinese team approved to test gene-edited cells in people with lung cancer. Nature 535: 476–477.
Didigu, CA, Wilen, CB, Wang, J. 2014. Simultaneous zinc-finger nuclease editing of the HIV-1 coreceptors CCR5 and CXCR4 protects CD4+ T cells from HIV-1 infection. Blood 123: 61–69.
Doudna, JA, Charpentier, E. 2014. Genome editing: the new frontier of genome engineering with CRISPR-Cas 9. Science 346: 1258096.
Finzi, D, Hermankova, M, Pierson, T, et al. 1997. Identification of a reservoir for HIV-1 in patients in highly active antiretroviral therapy. Science 278: 1295–1300.
Gallo, RC, Sarin, PS, Gelmann, EP, et al. 1983. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome. Science 220: 865–867.
Gilbert, LA, Horlbeck, MA, Adamson, B, et al. 2014. Genome-scale CRISPR-mediated control of gene repression and activation. Cell 159: 647–661.
Hall, B, Limaye, A, Kulkarni, AB. 2009. Overview: generation of gene knockout mice. Curr Protoc Cell Biol Chapter 19: Unit 188.8.131.52.1–17.
Harrison, PT, Hart, S. 2017. A beginner’s guide to gene editing. Exp Physiol. Doi: 10.1113/EP086047.
Heckl, D, Kowalczyk, MS, Yudovich, D, et al. 2014. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nat Biotechnol 32: 941–946.
Hermankova, M, Siliciano, JD, Zhou, Y, et al. 2003. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol 77: 7388–7392.
Hochheiser, K, Kueh, AJ, Gebhardt, T, et al. 2018. CRISPR-Cas9: a tool for immunological research. Eur J Immunol. Doi: 10.1002/eji.201747131.
Hou, W, Fang, C, Liu, J, et al. 2015. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody. Antivir Res 122: 101–111.
Hsu, PD, Lander, ES, Zhang, F. 2014. Development and application of CRISPR-Cas9 for genome engineering. Cell 157: 1262–1278.
Hu, W, Kaminski, R, Yang, F. et al. 2014. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci USA 111: 11461–11466.
Hütther, G, Nowak, D, Mossner, M, et al. 2009. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med 360: 692–698.
Jia, Y, Chen, L, Ma, Y, et al. 2015. To know how a gene works, we need to redefine it first but then, more importantly, to let the cell itself decide how to transcribe and process its RNAs. Int J Biol Sci 11: 1413–1423.
Kaminski, R, Chen, Y, Fischer, T, et al. 2016. Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas 9 gene editing. Sci Rep 6: 22555.
Kang, H, Minder, P, Park, MA, et al. 2015. CCR-5 disruption in induced pluripotent stem cells using CRISPR/Cas 9 provides selective resistance of immune cells to CCR5-tropic HIV-1 virus. Mol Ther Nucleic Acids 4, e268.
Kato, T, Takada, S. 2016. In vivo and in vitro disease modeling with CRISPR/Cas 9. Brief Funct Genom 2016: 1–12.
Kawai, T, Akira, S. 2010. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 11: 373–384.
Khalili, K, Kaminski, R, Gordon, J, et al. 2015. Genome editing strategies: potential tools for eradicating HIV-1/AIDS. J Neurovirol 21: 310–321.
Kim, JM, Chen, DS. 2016. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol 27: 1492–1504.
Kondo, T, Kawai, T, Akira, S. 2012. Dissecting negative regulation of toll-like receptor signaling. Trends Immunol 33: 449–458.
Li, C, Guan, X, Jin, W, et al. 2015. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas 9. J Gen Virol 96: 2381–2393.
Liu, R, Paxton, WA, Choe, S, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367–377.
Mandal, PK, Ferreira, LM, Collins, R, et al. 2014. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas 9. Cell Stem Cell 15: 643–652.
Mali, P, Aach, J, Stranges, PB, et al. 2013a. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31: 833–838.
Mali, P, Yang, L, Esvelt, KM, et al. 2013b. RNA-guided human genome engineering via Cas9. Science 339: 823–826.
Malina, A, Mills, JR, Cencic, R, et al. 2013. Repurposing CRISPR/Cas9 for in situ functional assays. Genes Devel 27: 2602–2614.
Reardon, S. 2016. First CRISPR clinical trial gets green light from US panel: the technique’s first test in people could begin as early as the end of the year. Nature News, 22 June. Doi:10.1038/nature.2016.20137.
Samson, M, Libert, F, Doranz, BJ, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722–725.
Sánchez-Rivera, FJ, Jacks, T. 2015. Applications of the CRISPR-Cas9 system in cancer biology. Nat Rev Cancer 15: 387–395.
Sánchez-Rivera, FJ, Papagiannakopoulos, T, Romero, R, et al. 2014. Rapid modelling of cooperating genetic events in cancer through somatic genome editing. Nature 516: 428–431.
Schumann, K, Lin, S, Boyer, E, et al. 2015. Generation of knock-in primary human T cells using Cas 9 ribonucleoproteins. Proc Natl Acad Sci USA 112: 10437–10442.
Shalem, O, Sanjana, NE, Hartenian, E, et al. 2014. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343: 84–87.
Siliciano, JD, Kajdas, J, Finzi, D, et al. 2003. Long-term follow up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9: 727–728.
Su, S, Hu, B, Shao, J, et al. 2016. Crispr-Cas 9 medaited efficient PD-1 disruption on human primary T cells from cancer patients. Sci Rep 6: 20070.
Tang, S, Chen, T, Yu, Z, et al. 2014. RasGRP3 limits toll-like receptor-triggered inflammatory response in macrophages by activating Rap1 small GTPase. Nat Comm 5: 4657.
Tebas, P, Stein, D, Tang, W, et al. 2014. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV-1. N Engl J Med 370: 901–910.
Thurtle-Schmidt, DM, Lo, TW. 2018. Molecular biology at the cutting edge: a review on CRISPR-Cas9 gene editing for undergraduates. Biochem Mol Biol Educ. Doi: 10.1002/bmb.21108.
Wang, G, Zhao, N, Berkhout, B, et al. 2016. CRISPR-Cas9 can inhibit HIV-1 replication but NHEJ repair facilitates virus escape. Mol Ther 24: 522–526.
Wong, JK, Hezaret, M, Günthard, HF, et al. 1997. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291–1295.
Xia, P, Wang, S, Xiang, Z, et al. 2015. IRTKS negatively regulates antiviral immunity through PCBP2 sumoylation-mediated MAVS degradation. Nat Comm 6: 8132.
Xue, HY, Ji, LJ, Gao, AM, et al. 2015. CRISPR-Cas9 for medical genetic screens: applications and future perspectives. J Med Genet 53: 91–97.
Xue, W, Chen, S, Yin, H, et al. 2014. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514: 380–384.
Ye, L, Wang, J, Beyer, AI, et al. 2014. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci USA 111: 9591–9596.